Skip to main content

In 18 clinical studies of various topical formulations of clindamycin phosphate using placebo vehicle and/or active comparator drugs as controls, patients experienced a number of treatment emergent adverse dermatological events (see table below).

 

Number of patients reporting events
Treatment Emergent
Adverse Event
Solution
n=553 (%)
Gel
n=148 (%)
Lotion
n=160 (%)
Burning
62 (11)
15 (10)
17 (11)
Itching
36 (7)
15 (10)
17 (11)
Burning/Itching
60 (11)
# (-)
# (-)
Dryness
105 (19)
34 (23)
29 (18)
Erythema
86 (16)
10 (7)
22 (14)
Oiliness/Oily Skin
8 (1)
26 (18)
12 * (10)
Peeling
61 (11)
# (-)
11 (7)
# not recorded     
* of 126 subjects